Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Protara Therapeutics (TARA) Shares Outstanding (Weighted Average) (2016 - 2026)

Protara Therapeutics' Shares Outstanding (Weighted Average) history spans 14 years, with the latest figure at $57.5 million for Q1 2026.

  • Quarterly Shares Outstanding (Weighted Average) rose 41.35% to $57.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $57.5 million through Mar 2026, up 41.35% year-over-year, with the annual reading at $13.5 million for FY2025, 34.35% down from the prior year.
  • Shares Outstanding (Weighted Average) came in at $57.5 million for Q1 2026, up from $13.5 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $57.5 million in Q1 2026 to a low of $11.3 million in Q1 2022.
  • The 5-year median for Shares Outstanding (Weighted Average) is $11.4 million (2024), against an average of $20.8 million.
  • The largest YoY upside for Shares Outstanding (Weighted Average) was 256.43% in 2025 against a maximum downside of 34.35% in 2025.
  • Protara Therapeutics' Shares Outstanding (Weighted Average) stood at $11.3 million in 2022, then grew by 0.64% to $11.3 million in 2023, then soared by 81.73% to $20.6 million in 2024, then tumbled by 34.35% to $13.5 million in 2025, then surged by 325.63% to $57.5 million in 2026.
  • Per Business Quant, the three most recent readings for TARA's Shares Outstanding (Weighted Average) are $57.5 million (Q1 2026), $13.5 million (Q4 2025), and $41.8 million (Q3 2025).